Brand Name
Rivfloza
Generic Name
Nedosiran
View Brand Information FDA approval date: February 19, 2024
Form: Injection
What is Rivfloza (Nedosiran)?
RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 and relatively preserved kidney function, e.g., eGFR ≥30 mL/min.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment